Search
Search Results
-
Current neoadjuvant therapy for operable locally advanced esophageal cancer
Locally advanced esophageal cancer has a poor prognosis, while an increasing number of patients are diagnosed with that. Neoadjuvant therapy has...
-
Total neoadjuvant therapy for each locally advanced rectal cancer?
The treatment paradigm for locally advanced rectal cancer has changed in recent years. Neoadjuvant radiochemotherapy followed by total mesorectal...
-
Preoperative stereotactic radiosurgery as neoadjuvant therapy for resectable brain tumors
PurposeStereotactic radiosurgery (SRS) is a method of delivering conformal radiation, which allows minimal radiation damage to surrounding healthy...
-
Neoadjuvant therapy for pancreatic cancer
Patients with localized pancreatic ductal adenocarcinoma (PDAC) are best treated with surgical resection of the primary tumour and systemic...
-
A Paradigm Shifts: Neoadjuvant Therapy for Clearly Resectable Pancreatic Cancer
Over the past decade, neoadjuvant therapy has become the standard of care for patients with borderline resectable and locally advanced pancreatic...
-
Neoadjuvant Therapy in Melanoma: Where Are We Now?
Purposeof ReviewThis review summarizes the current state of neoadjuvant immunotherapy and targeted therapy for locoregionally advanced melanoma.
... -
Neoadjuvant Photodynamic Therapy: An Updated Therapeutic Approach for Non-Melanoma Skin Cancers
Non-melanoma skin cancers (NMSCs) are the most common malignancy and surgical excision is considered treatment of choice for the majority of cases....
-
Total neoadjuvant therapy in rectal cancer
Total neoadjuvant therapy is a novel approach for locally advanced rectal cancer. The optimal treatment sequence is, however, a matter of debate and...
-
Radiation Management for Breast Cancer After Neoadjuvant Therapy
Purpose of ReviewNeoadjuvant chemotherapy (NAC) utilization is an important part of breast cancer therapy. Recent advances call into question the...
-
Timing After Neoadjuvant Therapy Predicts Mortality in Patients Undergoing Esophagectomy: a Propensity Score–Matched Analysis
BackgroundCurrently most surgeons allow 6–12 weeks after neoadjuvant therapy prior to recommending esophagectomy. Given that complete pathologic...
-
Neoadjuvant nivolumab plus bevacizumab therapy improves the prognosis of triple-negative breast cancer in humanized mouse models
BackgroundThe combination of immune checkpoint inhibitors and anti-angiogenic agents has been proposed as a promising strategy to improve the outcome...
-
Pathologic Complete Response, Total Neoadjuvant Therapy and the Survival Paradox in Locally Advanced Rectal Cancer
BackgroundPathologic complete response (pCR) after preoperative chemoradiation (nCRT) correlates with improved overall survival for patients with...
-
Multimodal assessment after total neoadjuvant therapy versus standard neoadjuvant chemoradiotherapy in locally advanced rectal cancer accurately predicts complete responders
PurposeThis study aimed to compare local regrowth rates after total neoadjuvant therapy (TNT) versus standard neoadjuvant chemoradiotherapy (SNCRT)...
-
Association of clinical biomarkers and response to neoadjuvant therapy in breast cancer
IntroductionNeoadjuvant therapy is an essential component of multimodality therapy for locally advanced breast adenocarcinoma (BC). Complete...
-
Prognostic impact of tumor budding in rectal cancer after neoadjuvant therapy: a systematic review and meta-analysis
BackgroundTumor budding (TB) is a negative prognostic factor in colorectal cancer; however, its prognostic impact following neoadjuvant therapy for...
-
Long-Duration Neoadjuvant Therapy with FOLFIRINOX Yields Favorable Outcomes for Patients Who Undergo Surgery for Pancreatic Cancer
BackgroundIn 2023 alone, it’s estimated that over 64,000 patients will be diagnosed with PDAC and more than 50,000 patients will die of the disease....
-
The immune microenvironment after neoadjuvant therapy compared to upfront surgery in patients with pancreatic cancer
BackgroundPatients with resectable and borderline resectable pancreatic ductal adenocarcinoma increasingly receive neoadjuvant therapy prior to...
-
Prognostic impact of desmoplastic reaction in esophageal squamous cell carcinoma patients with neoadjuvant therapy
AimThis study aimed to examine the prognostic value of desmoplastic reaction (DR) in esophageal squamous cell carcinoma (ESCC), particularly in...
-
Neoadjuvant Therapy for Duodenal and Ampullary Adenocarcinoma: A Systematic Review
BackgroundThe role of systemic therapy in the management of ampullary (AA) and duodenal adenocarcinoma (DA) remains poorly understood. This study...
-
Future direction of total neoadjuvant therapy for locally advanced rectal cancer
Despite therapeutic advancements, disease-free survival and overall survival of patients with locally advanced rectal cancer have not improved in...
